Top Markets
#1 Black Phoenix Black Phoenix +195.57%
#2 Islamic Coin Islamic Coin +158.05%
#3 Glidr Glidr +84.34%
#4 Gold Park Gold Park +34.97%
#5 Acurast Acurast +27.36%
#6 Cryptopia Cryptopia +21.79%
#7 Quantum Resistant Ledger Quantum Resistant Ledger +17.37%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +16.57%
#9 Test Test +14.82%
#10 Playnance Playnance +14.01%
Coin of the day
Black Phoenix Black Phoenix
設定
言語
日本
通貨
USD
テーマ
Regenicin, Inc. Regenicin, Inc.

Regenicin, Inc.

RGIN
株式のランク #41590
Regenicin, Inc. is dedicated to the development and commercialization of... Regenicin, Inc. is dedicated to the development and commercialization of advanced tissue-engineered skin replacement technologies. Its product line features NovaDerm, a sophisticated multi-layered living and cultured skin substitute engineered for treating burn injuries, alongside TempaDerm, which addresses more localized wound areas like ulcers. These innovative solutions aim to rejuvenate the characteristics of healthy human skin, finding application in burn therapy, chronic wound management, and various plastic surgery procedures. Incorporated in 2007 and based in Little Falls, New Jersey, the company was previously known as Windstar, Inc., adopting the Regenicin, Inc. name in July 2010.
株価
$0.0001
最終同期: 2026-08-11
時価総額
$15.35K
変化（1日）
0.00%
変化（1年）
0.00%
国
US
取引 Regenicin, Inc. (RGIN)

カテゴリー

Healthcare
Regenicin, Inc.（RGIN）の利益
2026 時点の利益 TTM: 0
Regenicin, Inc. の最新の財務報告によると、同社の現在の利益は 0 です。2026 年には 0 の利益を上げ、これは 2026 年の利益 0 と 同等 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Regenicin, Inc. の利益の推移（2026 〜 2026）
各年末の利益
年 利益 変化
提供された日付のデータは十分ではありません。
同業他社の利益
企業 利益 利益の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE